Overview
- WHO released new global guidelines on child and adolescent obesity on Wednesday, Oct. 7, 2026, and established an age-based treatment pathway that bars pharmacologic, surgical and device interventions for children aged 0–9.
- For adolescents aged 10–19, the guidance allows approved medicines including GLP-1s only after a supervised multimodal lifestyle program has failed and recommends bariatric surgery only for physically and mentally mature teens under strict conditions.
- The agency strongly recommends structured, caregiver-involved programs that combine tailored diets, daily physical activity and behaviour-change support and conditionally endorses supervised digital tools for delivery.
- WHO warned current evidence on long-term safety and effectiveness of GLP-1 medicines in children is insufficient, said it is monitoring ongoing trials, and may revise recommendations as new data emerge.
- The guideline reframes childhood obesity as a chronic, relapsing condition that needs sustained follow-up and equitable access to healthy foods and activity, a stance that could reshape clinical practice, policy and family care options where GLP-1 use and regulatory approvals are already rising.